June 23, 2026
1 min watch
In this video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights recent coverage of the myriad ways federal policies are impacting health care, from Medicare Part D coverage to student loans.
“There is so much going on in how our government interfaces with our health care system, particularly pertinent to rheumatology,” he said. “We have several stories on Medicare Part D, and how restrictive this is for certain rheumatology drugs.
“We also dig into some of the issues at the CDC, and this time focus on the student loan cap, and how this is going to impact the future of physicians,” he added.
Turning to science, Calabrese discussed a recent Q&A with Gregg Silverman, MD, of the New York University Grossman School of Medicine, on the impacts of the microbiome on lupus.
Silverman and colleagues have published data suggesting a common gut bacterium may be implicated in lupus kidney disease, and could potentially alter the diagnosis and treatment of lupus nephritis going forward.
“And finally we turn back to science and some brilliant work done by Gregg Silverman on the microbiome and lupus, and lupus nephritis,” Calabrese said. “I think this is really a frame shift in the way we think about microbiomics.”
For more information:
Leonard H. Calabrese, DO, can be reached at calabrl@ccf.org or at rheumatology@healio.com.
Sources/Disclosures
Source:
Healio Interview
Disclosures:
Calabrese reports being a medical advisor for OpenEvidence, as well as professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
